Swedish Orphan Biovitrum (Sobi) has been approached by bidders, but the company is not revealing the names of the interested parties.
The company recently issued a statement saying “that it has received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company.”
Word of the proposed takeover has been circulating for several days. Sobi recently brought in Goldman Sachs to advise it. The company is currently valued at about $3.5 billion, though its shares surged about 24 percent as word of the buyout bid spread. Sobi focuses on treatments for rare diseases, particularly genetic and inflammatory diseases.